Pharma News
FDA Approves AstraZeneca’s Ultomiris for Neuromyelitis Optica Spectrum Disorder
![](https://meefro.com/wp-content/uploads/2024/03/FDA-Approves-AstraZenecas-Ultomiris-for-Neuromyelitis-Optica-Spectrum-Disorder-780x470.png)
Action marks the first FDA approval of a long-acting treatment for adult patients with neuromyelitis optica spectrum disorder who are positive for the anti-aquaporin-4 antibody.
Source link
#FDA #Approves #AstraZenecas #Ultomiris #Neuromyelitis #Optica #Spectrum #Disorder